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ABSTRACT 
 
Raised albumin-creatinine ratio (ACR) is an indicator of microvascular damage and renal 
disease. We aimed to identify genetic variants associated with raised ACR and study the 
implications of carrying multiple ACR-raising alleles with metabolic and vascular related 
disease. We performed a genome-wide association study of ACR using 437,027 
individuals from the UK Biobank in the discovery phase, 54,527 more than previous 
studies, and followed up our findings in independent studies. We identified 62 
independent associations with ACR across 56 loci (P<5x10-8), of which 20 were not 
previously reported. Pathway analyses and the identification of 20 of the 62 variants (at 
r
2
>0.8) coinciding with signals for at least sixteen related metabolic and vascular traits, 
suggested multiple pathways leading to raised ACR levels. After excluding variants at the 
CUBN locus, known to alter ACR via effects on renal absorption, an ACR genetic risk 
score was associated with a higher risk of hypertension, and less strongly, type 2 diabetes 
and stroke. For some rare genotype combinations at the CUBN locus, most individuals 
had ACR levels above the microalbuminuria clinical threshold. Contrary to our 
hypothesis, individuals carrying more CUBN ACR-raising alleles, and above the clinical 
threshold, had a higher frequency of vascular disease. The CUBN allele effects on ACR 
were twice as strong in people with diabetes – a result robust to an optimization-
algorithm approach to simulating interactions, validating previously reported gene-
diabetes interactions (P≤4x10-5). In conclusion, a variety of genetic mechanisms and 
traits contribute to variation in ACR.  
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz243/5599707 by U
niversity of Exeter user on 29 O
ctober 2019
3 
 
INTRODUCTION 
 
High urinary albumin excretion is a marker of chronic kidney disease (CKD) and a 
predictor of mortality and cardiovascular events in the general population and in clinical 
populations, such as individuals with diabetes (1). Moreover, raised albuminuria is 
believed to be indicative of systemic endothelial microvascular damage (2). Albumin-
creatinine ratio (ACR) is an accepted marker of urinary excretion of albumin (3) 
available in large numbers of individuals through routine clinical testing.  
 
Genetic studies of ACR are important as individuals with raised ACR levels due to 
genetics affecting tubular reabsorption, for example, may not be at higher risk of vascular 
disease. Conversely, individuals with low ACR levels due to genotypes that directly alter 
ACR may be missed in clinical tests for microvascular damage. Genetic studies of ACR 
may identify new, or clarify the role of known, pathways altering microvascular function 
or kidney function, or both. 
 
Prior to the availability of data from the UK Biobank, previous genetic association 
studies had identified only one region of the genome robustly associated with ACR at the 
cubilin (CUBN) locus (4-6). Associations were mainly represented by a common single-
nucleotide polymorphism (SNP) (rs1801239) with a minor allele frequency (MAF) of 
10% (5). In addition, van Zuydam et al. showed a putative association between a signal 
on chromosome 6 (GABRR1) and diabetic microalbuminuria (7). Most recently, a rare 
SNP (rs141640975) with a MAF of 0.8% was identified as associated with albuminuria 
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through exome sequencing (8). Ahluwalia et al. also identified evidence of association 
for three genes (HES1, CDC73 and GRM4) after performing gene-based tests. Both 
Teumer et al. and Ahluwalia et al. provided evidence that the CUBN variant has a 3 to 4-
fold larger effect in people with diabetes. Teumer et al. identified two additional loci with 
stronger effects in individuals with diabetes (RAB38/CTSC and HS6ST1).  
 
Mutations in the CUBN gene cause an autosomal recessive disorder, Imerslund Gräsbeck 
Syndrome, characterized by Vitamin B12 malabsorption and, in many cases, mild 
proteinuria (9). Proteinuria in this context is likely to be due to a defect of the cubilin 
receptor which binds albumin in renal tubuli thus decreasing albumin reabsorption (10). 
Therefore, the CUBN variant may alter ACR directly without being associated with renal 
damage. 
 
To understand more about the genetic factors associated with variation in ACR and study 
the implications of carrying multiple ACR-raising alleles with metabolic and vascular 
related disease, we performed a genome-wide association study (GWAS) of ACR using 
437,027 individuals from the UK Biobank study with subsequent replication using 
publicly available data from the CDKGen consortium (5) and the EXTEND study. Our 
study follows those from Haas et al. and Zanetti et al. who identified 46 and 21 genetic 
associations with ACR at the conventional P<5x10
-8
 threshold respectively in smaller 
subsets of UK Biobank participants (N=382,500 and N=218,450 discovery sets 
respectively) (11, 12). In addition to the identification of 20 novel loci in our larger 
sample size, we focused our analyses on those very difficult to perform in the context of a 
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GWAS consortium of many smaller studies and not performed by Haas et al. These 
analyses included testing haplotype effects at the CUBN locus, colocalization of genetic 
associations, and gene-disease interactions in the UK Biobank. 
 
RESULTS 
 
Clinical characteristics of the 437,027 UK Biobank individuals of European ancestry and 
with ACR available are presented in Table 1 and Supplementary Figure 1. The 
characteristics of the EXTEND study individuals are also presented in Table 1.  
 
GWAS of ACR in UK Biobank identified sixty-two associated variants across fifty-
six loci, twenty of which have not been previously associated with ACR. 
We identified 62 statistically independent SNPs in 56 loci associated with ACR at 
P<510-8 of which 42 reached P<610-9, a threshold that we estimate reflects better the 
5% type 1 error rate (13). Of the 62 associations, 18 were located in loci not previously 
reported to be associated with ACR, and 2 were in low linkage disequilibrium (r
2
<0.1) 
with lead SNPs previously reported. Of these 20 associations, 9 reached P<610-9 (Table 
2) The LD score regression intercept was 1.05 indicating limited inflation due to 
population stratification. Conditional analysis revealed five loci containing one additional 
signal and one containing two additional signals (CUBN) (Supplementary Table 1 and 
Supplementary Figs. 2-3).  
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Genetic variants validate in independent data. 
We used summary statistics from the CKDGen consortium meta-analysis of 54,451 
individuals (5) to check for directional consistency of the ACR associated variants. Of the 
62 variants, 47 were available in the summary statistics (including proxy variants at 
r
2
>0.8). The effect estimates of 39/47 SNPs showed directional consistency 
(Pbinomial<0.0001) (Supplementary Table 2). The variants not previously identified also 
showed strong evidence of validation - 15 of the 20 were present in the CKDGen 
consortium (or their proxies), and 11 of these were directionally consistent. In addition, 
8/15 analyzed by the CKDGen consortium reaching P<610-9 in our analysis, 7/8 effect 
estimates were directionally consistent. Of the 47 SNPs, the maximum variance 
explained by a single SNP in UK Biobank was 0.03%. We note the power to detect an 
association at P=510-8 explaining 0.03% of the variance in 54.451 individuals was 8%, 
and 76% at P=810-4 after Bonferroni correction for 62 tests (0.05/62). In the EXTEND 
study of 5,679 individuals with measures of ACR, the overall variance explained by all 
62 ACR-associated SNPs was 0.61% of the inverse-normalized trait (Supplementary 
Table 3). 
 
High genetic risk for ACR increases risk of microalbuminuria. 
We next assessed the risk of being above the clinical threshold of 3 mg/mmol for 
microalbuminuria using a genetic risk score (GRS) for ACR. A one unit increase in the 
ACR GRS was equivalent to 0.07 mg/mmol increase in ACR. In the UK Biobank, a one 
unit increase in the GRS for ACR was associated with a higher risk for being over the 
clinical threshold and this effect was stronger in men (odds-ratio (OR)=1.124, 95%CI: 
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1.116–1.133, P=4.0x10-202) than women (OR=1.059, 95%CI: 1.053–1.065, P=3.410-85; 
Pinteraction=9.3x10
-34
). To avoid inflated effect estimates due “winner’s curse” we repeated 
this analysis in the independent EXTEND study. A one unit higher genetic risk score for 
ACR was associated with an overall OR=1.062 (95%CI: 1.015 – 1.110, P=0.009). When 
restricting the analysis to CUBN raising alleles, we showed that the 19.9% of UK 
Biobank individuals carrying at least one CUBN raising allele had an OR=1.153 (95%CI: 
1.122–1.185, P=1.0x10-24) for being above the clinical threshold compared to those 
carrying no ACR-raising alleles at the locus.  
 
Individuals with a genetic risk score for high ACR have a higher risk of 
hypertension. 
We next tested the combined role of ACR-associated variants in five diseases related to 
vascular dysfunction in the UK Biobank: hypertension, type 2 diabetes (T2D), coronary 
artery disease (CAD), chronic kidney disease (CKD), and stroke. We reasoned this would 
reveal whether individuals with a high ACR genetic risk score were at high risk of 
vascular-related disease. The genetic risk score of raised ACR was associated with higher 
risk of hypertension [OR=1.013, 95%CI: 1.010-1.016, P=1.6x10
-16
], but much weaker or 
no evidence of association with stroke [OR=1.011, 95%CI: 1.001–1.022, P=0.027], T2D 
[OR=1.008, 95%CI: 1.000–1.017, P=0.045], CAD [OR=1.004, 95%CI: 0.999–1.010, 
P=0.13] and CKD [OR=0.996, 95%CI: 0.982–1.010, P=0.59]. These results were not 
strongly influenced by the large effect of SNPs in CUBN - we obtained similar results 
when using a GRS excluding the three variants in CUBN (Supplementary Table 4). We 
had no direct measure of vascular disease and therefore we were unable to establish if the 
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association between the ACR genetic risk score and hypertension was directly due to 
vascular dysfunction, but they imply that a higher genetic risk score for ACR is not 
benign.  
 
Analyses of pathways and variants previously associated with vascular and 
metabolic traits implicate multiple mechanisms.  
We next examined the 62 ACR-associated variants for pleiotropic effects. We observed 
these variants to likely influence ACR through a wide variety of mechanisms, many of 
which are known to be causally related to, or strongly associated with, vascular diseases 
and related traits. Previous GWAS had identified 20 of the ACR associated variants (or 
those in strong LD (r
2
 >0.8)) as associated with a trait related to metabolic, inflammatory 
or vascular disease at genome-wide significance levels (P<5x10
-8
). These associations 
were with a wide variety of traits, including blood lipid profiles, fasting glucose, blood 
pressure, and type 2 diabetes (Supplementary Table 5). Two variants represented 
known type 2 diabetes signals (a variant in the ARL15 locus and a variant in the SNX17 
locus that is in LD with highly pleiotropic variants at the GCKR locus (r
2
>0.85)), three 
represented known coronary artery disease signals (a variant near KCKN5, one near 
TRIB1 and one in the intron of CCDC97) and one represented a known blood pressure 
signal (a variant in HOTTIP). These variants are likely examples of variants with 
pleiotropic effects that affect ACR through additional mechanisms. For seven of the 20 
ACR associated variants in strong linkage disequilibrium with known signals for other 
traits, data was available to perform a co-localization analysis. All seven showed a high 
probability (>0.7) that variants associated with ACR represented the same signal as that 
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previously reported – including with those for blood lipid profiles, fasting glucose, blood 
pressure, and type 2 diabetes (Supplementary Table 6). Using MAGMA (14) we 
identified an enrichment of genes at associated loci involved in pathways related to lipid 
metabolism, genital and digestive tract development at P<0.05 after adjustment for 
multiple testing (Supplementary Table 7). We did not observe evidence of tissue 
enrichment for genes in the associated loci (Supplementary Figure 4). 
 
We observed three signals at the previously reported CUBN locus.  
We identified three independent SNPs associated with ACR at the CUBN locus 
(rs45619139, rs45551835 and rs141640975). These variants had common (rs45619139; 
minor allele frequency (MAF) 10.1%), low (rs45551835; MAF 1.4%) and rare 
(rs141640975; MAF 0.3%) allele frequencies and were weakly correlated (low linkage 
disequilibrium).  The minor alleles at the common, low frequency and rare variants were 
associated with 0.06, 0.19 and 0.46 standard deviation higher ACR, respectively (Table 3 
and Figure 1). The common variant previously reported was rs1801239, but this 
association was abolished after the adjustment for stronger lead SNP rs45619139 in the 
UK Biobank (r
2
=0.78). The low frequency (rs45551835) and rare (rs141640975) variants 
both alter the amino acid sequence of CUBN (g.16932384G>A, p.Ala2914Val) and 
(g.16992011G>A, p.Ala1690Val) respectively, and have previously been associated with 
variation in ACR. 
 
Haplotype analysis suggests alleles at the CUBN locus have additive effects on ACR.  
To test the effects of carrying more than one of the three CUBN variants, and whether in 
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cis (one copy of the CUBN gene carrying 2 or 3 minor alleles) or trans (both copies of the 
CUBN gene carrying at least one minor allele), we estimated the haplotypes formed by 
the three SNPs. The correlation between the three SNPs was low. However, the D’ 
measure of linkage disequilibrium was high, suggesting a limited number of 
recombination events have occurred between the three variants: D’=1 between 
rs141640975 and rs45551835 and between rs141640975 and rs45619139, and D’=0.92 
between rs45551835 and rs45619139. The variants formed five out of a maximum of 
eight haplotypes (Table 4). As expected from its very low frequency, the minor allele (A) 
at the rare variant rs141640975 occurred on only one haplotype – together with the 
common alleles at the two other variants (G-C-A; frequency=0.3%) and had the largest 
effect (0.48 SD). All four potential haplotypes formed by the common (rs45619139) and 
low frequency (rs45551835) CUBN variants were detected – indicating a recombination 
event must have occurred between them (or, less likely, a second identical mutation). 
However, the ACR-raising allele (A) at the low frequency variant occurred much more 
frequently on the same haplotype with the ACR-raising allele at the common variant (G) 
(A-G-G; frequency=1.3%), rather than with the ACR-lowering allele (C) (A-C-G; 
frequency=0.1%; Table 4). The A-G-G haplotype was associated with 0.2 SDs higher 
ACR compared to the commonest haplotype, formed by the three common alleles (G-C-
G). This effect was larger than that of the two haplotypes carrying only one of the ACR 
raising alleles for the low-frequency or common variant (A-C-G and G-G-G), consistent 
with an additive effect of the two alleles, suggesting that the presence of the two alleles in 
cis on the same haplotype did not change their effects (Table 4).   
 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz243/5599707 by U
niversity of Exeter user on 29 O
ctober 2019
11 
 
Carriers of ACR-raising CUBN alleles have higher disease frequency. 
We next classified UK Biobank individuals into 12 groups based on genotype 
combinations of the three CUBN variants (Supplementary Table 8 and Figure 2). We 
tested the hypothesis that people with clinically classifiably microalbuminuria partly due 
to their CUBN genetics would have a lower frequency of vascular related diseases 
compared to those without ACR raising alleles at the CUBN locus. We noted that for 
some very rare CUBN genotype combinations the majority of individuals would be 
classified as having microalbuminuria. For example, of the 25 individuals heterozygous 
at each of the three CUBN SNPs (<0.01% of the UK Biobank study), 21 (84%) had an 
ACR value that would classify them as having microalbuminuria (P<0.001 Fisher’s exact 
test, compared to individuals carrying no ACR raising alleles at the CUBN locus) (Figure 
2).  
 
We next selected all UK Biobank individuals above the clinical threshold for 
microalbuminuria to quantify the extent to which those with at least one ACR-raising 
allele at CUBN would have a lower frequency of vascular related disease compared to 
those without a CUBN raising allele. Of the 40,491/437,027 individuals above the clinical 
threshold for microalbuminuria, 31,592 carried no ACR-raising alleles at the CUBN 
locus. Contrary to our hypothesis that CUBN ACR-raising alleles are benign for vascular 
related diseases, people above the clinical threshold and carrying ACR-raising alleles at 
the CUBN locus had a higher frequency of CAD (carriers 11.2% vs non-carriers 10.2%, 
P=0.005), T2D (carriers 6.7% vs non-carriers 5.7%, chi-squared P<0.001) and stroke 
(carriers 3.4% vs non-carriers 2.9%, chi-squared P=0.006, Supplementary Table 8).  
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Additional ACR-diabetes interaction effects at the CUBN locus observed. 
We performed interaction analyses to test whether the 62 lead variants had stronger 
effects in individuals with diabetes as previously observed for the CUBN locus (5, 8). We 
replicated the statistical interactions between the common and rare CUBN signals and 
diabetes status. In people with diabetes, each copy of the minor allele for the common 
variant rs45619139 was associated with a 0.12 SD (95%CI: 0.08–0.15) effect on ACR 
(inverse-normalized). The observed effect in people without diabetes was 0.06 SD 
(95%CI: 0.05–0.06) (Pinteraction=110
-5
) (Table 5 and Supplementary Table 9). The 
minor alleles at the low frequency and rare CUBN variants also showed evidence of 
statistical interaction with diabetes status, with larger effects on ACR in people with 
diabetes (rs45551835 Pinteraction=610
-7
; rs141640975 Pinteraction=410
-5
). These types of 
interaction are prone to statistical artefacts, especially when dichotomising groups of 
people (15). We recently developed a negative control method based on an computational 
optimization algorithm to assess the likelihood of such artefacts (16) (url: 
https://github.com/drarwood/gags ) - after 1,000 repeated interaction analyses of groups 
of individuals sampled to have the same means and standard deviations of ACR as 
individuals with and without a diagnosis of diabetes, we observed an empirical P-value 
0.02 (19 of 1000 tests were more significant than the observed interaction at most). This 
suggests that the interaction was unlikely to be a statistical artefact of the differences in 
the two underlying distributions of ACR (Table 5 and Supplementary Figure 5). After 
accounting for multiple testing, we found no evidence of interaction for the remaining 59 
index variants outside of the CUBN locus with main effects on ACR (Supplementary 
Table 10).  
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When combining variants into a weighted GRS (excluding CUBN variants), we observed 
evidence of interaction with diabetes status, with the GRS having larger effects in people 
with diabetes (Pinteraction=210
-6
). After random sampling (described above) we observed 
an empirical Pinteraction=0.11, suggesting the interaction may not be specific to diabetes 
(Supplementary Figure 5). This T2D interaction may be a feature of metabolic disease 
in general because we also identified evidence of interaction between the ACR GRS and 
other diseases – all with stronger effects in cases than controls: hypertension (GRS  
cases=0.036, 95%CI: 0.034-0.038; GRS  controls=0.025, 95%CI: 0.023-0.027; Pinteraction 
=210-18), CKD (GRS cases=0.043, 95%CI: 0.030-0.056; GRS controls=0.031, 95%CI: 
0.030-0.033; Pinteraction=410
-05
), CAD (GRS cases=0.034, 95%CI: 0.030-0.039; GRS 
controls=0.032, 95%CI: 0.031-0.034; Pinteraction=310
-02
), and stroke (GRS cases=0.039, 
95%CI: 0.030-0.048; GRS controls=0.032, 95%CI: 0.031-0.034; Pinteraction=210
-02
). In 
contrast to a previous study (5), we found no evidence of a gene-diabetes interaction at 
the HS6ST1 locus (Pinteraction=0.76) or RAB38/CTSC locus (Pinteraction=0.06). 
 
DISCUSSION 
 
We performed a GWAS of ACR in 437,027 individuals from the UK Biobank and 
identified 62 SNPs in 56 loci associated with increased ACR. Of these, we identified 20 
associations not previously known, of which 9 reached a stricter significance threshold of 
P<610-9. Prior to the availability of the UK Biobank data, only one of these 56 loci 
(CUBN) was known to be associated with variation in ACR in individuals of European 
ancestry (5, 6, 8). Recent analysis, of smaller sets of unrelated individuals from the UK 
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Biobank, identified 46 and 22 variants associated with ACR. The 62 variants we 
identified include 41/46 loci reported by the recent Haas et al. analysis (11). The five 
detected by Haas et al. but not us, despite our larger sample size, fell below the GWAS 
threshold of P<5x10
-8 
(P-values ranged between 1.5x10
-5
 and 4.9x10
-8
). This difference 
may reflect sampling error between our analyses. A more recent analyses of the UK 
Biobank data by Zenetti et al. (12) identified 19 associations with urinary ACR, but this 
analysis identified 22 variants after splitting the data into a discovery and replication 
dataset. These three analyses of the same data show the value in different groups 
analysing large genetic datasets with different approaches. 
 
A higher GRS for ACR was associated with higher risk of being above the clinical 
threshold for ACR. Like the Haas et al. study, we showed that people with a high ACR 
genetic risk score were at higher risk of hypertension compared to those with a lower 
ACR, but there was no association with other diseases, including diabetes.  
 
Our analysis of individual variants suggested that a higher genetic ACR results from a 
wide range of pathogenic mechanisms. Twenty of 62 ACR-associated SNPs have been 
previously associated at genome-wide significance with metabolic, inflammatory and 
vascular diseases and related traits. We identified over 200 separate ACR-SNP–second 
trait association entries in the NHGRI GWAS catalog (17), although over half included 
highly pleiotropic GCKR variants in LD with the our signal in SNX17 (18). With the 
exception of the SNX17 signal near GCKR, there were notably few that were known 
blood pressure, diabetes or CAD signals, and of these, they were not the most strongly 
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associated variants for these traits suggesting that the variants identified as associated 
with ACR are likely pleiotropic. The only T2D variant apart from that near GCKR 
associated with ACR is that in ARL15, where the ACR raising allele is associated with 
higher risk of T2D, but with a much lower odds ratio (1.06 [95%CI: 1.04-1.09)] (19) than 
many other known T2D variants. The ACR raising allele at ARL15 is also associated with 
apparently paradoxical effects on body composition (20) and poorer kidney function as 
measured by eGFR (6). That 20 of the 62 ACR-associated signals were previously known 
signals for a wide variety of traits, together with our pathway analyses implicating lipid 
metabolism and gut and genital development suggests a wide variety of mechanisms 
involved in normal variation in ACR. In addition, we note that 19/20 variant-ACR 
associations we present as novel are available in a recent meta-analysis of eGFR by 
Wuttke et al. (21). Of these, 16/19 effect estimates are directionally consistent with 
eGFR, with 10/16 at P<0.05 and 4/16 at P<5x10
-8
. 
 
Compared to previous studies, we performed a more extensive analysis of the previously 
reported CUBN locus (4, 5). We showed that the low frequency ACR-raising allele at 
rs45551835 most often occurs in cis with the more common ACR-raising allele at 
rs45619139 but this haplotype was associated with ACR consistent with the additive 
effects of the two alleles.  
 
The association with hypertension indicates that disease processes underlie a high ACR 
GRS, rather than benign effects on kidney reabsorption and means that it would be 
inappropriate to tailor the clinical threshold to a person’s GRS for ACR. This is likely to 
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be the case even for people carrying ACR-raising genotypes at the CUBN locus. These 
alleles might have been expected to be benign on disease risk, but for individuals above 
the microalbuminuria threshold our results provide evidence of higher frequencies of type 
2 diabetes, coronary heart disease, and stroke among CUBN allele carriers compared to 
non-carriers.  
 
The availability of individual level data from a large study also allowed us to test for 
gene–diabetes status interactions more extensively than before. Teumer et al. (2016) and 
Ahluwalia et al. (2019) showed that the ACR raising minor-allele in CUBN had a 3 to 4-
fold effect in people with diabetes compared to controls. Teumer et al. also reported 
larger effects in individuals with diabetes for variants in the HS6ST1 and RAB38/CTSC 
loci. We tested these reported interactions and performed negative control experiments to 
control for the different distributions of ACR between people with and without diabetes 
(15). We replicated the previously reported interactions for the common and rare signal at 
the CUBN locus but did not find evidence of gene-diabetes interactions or main effects at 
the HS6ST1 or RAB38/CTSC loci.  
 
Our analysis had a number of strengths, including the availability of individual level data 
from a single large-study that provided homogeneous measures of ACR. Access to 
individual level data facilitated analyses that would otherwise be difficult to perform, 
including haplotype analysis, disease prevalence among rare genotype groups, and 
interaction analysis with follow-up negative control experiments. 
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The main limitations of our study include the cross-sectional nature of the associations 
with disease prevalence. We are presently limited in our ability to evaluate the impact of 
ACR on disease outcomes prospectively in the UK Biobank within individuals who do 
not report having kidney disease. Second, the rare and low-frequency nature of the 
genetic variants with the largest effects mean replication of these signals will be difficult 
in many studies given relatively small sample sizes. Third, we calculated ACR in 
individuals with albumin levels below assay detection limits. Albumin levels were set to 
study-specific limits of detection – an approach previously used by other GWAS analyses 
of ACR (5). Finally, further work needs to be undertaken in other ethnicities to determine 
whether the findings in our study replicate in other ancestries.  
 
In conclusion, we have performed one of the largest genetic association studies on ACR 
and have gained further insight into the biological causes and clinical implications of 
raised ACR. 
 
MATERIALS AND METHODS 
 
Study individuals 
We used 437,027 UK Biobank individuals that had measures of ACR and were classified 
as European ancestry through principal components analyses and a k-means clustering 
approach using the first 4 principal components and 1000 Genomes Project samples as 
reference ancestral centers.  
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Albumin-creatine ratio in UK Biobank 
Measures of ACR were derived using urinary levels of albumin and creatinine. Albumin 
was measured in the UK Biobank samples using immuno-turbidimetric analysis method 
(Randox Bioscience, UK) while creatinine was measured using enzymatic analysis 
method (Beckman Coulter, UK). If albumin was <6.7 mg/L (the assay detection level in 
UK Biobank) then albumin was set at 6.7 mg/L prior to the calculation of the ratio, an 
approach consistent with previous studies (5).  
 
Albumin-creatine ratio in EXTEND 
Albumin and creatinine were measured in samples using immuno-turbidimetric and 
enzymatic methods, respectively. If albumin was <2.9 mg/L (the assay detection level) 
then albumin was set at 2.9 mg/L prior to the calculation of the ratio. 
 
Genome-wide association analysis 
Genetic associations for inverse-normalized ACR were tested using a linear-mixed model 
approach, implemented in BOLT-LMM (22). Models were adjusted for baseline age, sex, 
study center, and genotyping array. Imputed genotypes from the Haplotype Reference 
Consortium (HRC) from the UK Biobank were used(23). Variants with imputation 
quality (INFO) <0.3 or minor allele frequency (MAF) <0.1% were excluded. After 
quality control, 12,082,474 variants for association analysis remained. Lead SNPs were 
defined as those with the smallest P-value. Locus boundaries were defined using a ±0.5 
Mb distance from the lead SNP. Conditional analysis was performed by subsequently 
adding all lead SNPs for each locus as covariates. 
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Lookups of associations using summary statistics from the CKDGen consortium 
We downloaded summary statistics from the latest meta-analysis of ACR performed by 
CKDGen consortium to enable a comparison of directions of estimated effects for SNPs 
associated with ACR in the UK Biobank (5). We used proxies with r
2
>0.8 within 500kb 
if unavailable in CKDGen. 
 
Variation explained and validation of GRS in the EXTEND study 
We used the Exeter 10,000 (EXTEND) study to calculate the variance explained by 
discovered genetic associations in an independent cohort. EXTEND is a population-based 
study in the South West of England. Genotyping was performed using the Illumina 
Infinium Global Screening Array. Imputation of genotypes was performed using the 
Haplotype Reference Consortium (HRC) imputation reference panel (24). Analyses were 
based on 5,679 individuals with genotype data and measures of ACR. Association 
analyses were carried out using RVTEST, adjusting for relatedness and ancestry through 
a genomic relationship matrix (25). 
 
Genetic risk score derivation for raised ACR  
A weighted ACR genetic risk score (GRS) was calculated for each participant using the 
index variants identified from the UK Biobank analysis. Dosages were re-coded to ACR-
increasing alleles prior to weighting using the respective effect sizes observed in the UK 
Biobank. A weighted score was subsequently calculated as the sum of the weighted 
dosages (Equation 1) prior to re-scaling to reflect the number of ACR increasing alleles 
(Equation 2).  
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 Weighted score = 1 × SNP1 + 2 × SNP2 + … n × SNPn.  
(1) 
      
                       
∑ 
 
(2) 
 
Testing the ACR genetic risk score against risk of clinically defined microalbuminuria 
We tested whether a higher ACR genetic risk score was associated with being above the 
3 mg/mmol clinical threshold (NICE, https://www.nice.org.uk/guidance/cg182) for 
microalbuminuria using logistic regression.  
 
Testing whether a high ACR genetic risk score is associated with diabetes and vascular 
related disease. 
We used logistic regression to test the combined role of ACR-associated variants in five 
diseases related to vascular dysfunction and diabetes in the UK Biobank - hypertension, 
type 2 diabetes (T2D), coronary heart disease (CAD), chronic kidney disease (CKD) and 
stroke. Disease definitions were derived using a combination of questionnaire data, 
hospital episode statistics and interviews. Hypertension was defined as a systolic blood 
pressure of >140 mmHg, or a diastolic blood pressure of >90 mmHg, or the report of 
blood pressure medication usage using the baseline UK Biobank questionnaire. T2D was 
defined through self-report of diabetes using the UK Biobank questionnaire at baseline, 
>35 years of age, and without reporting of insulin use within the first year of diagnosis. 
We excluded individuals reporting diabetes diagnosed less than one year prior to baseline 
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data collection (N = 1,757) to exclude those who may be on insulin treatment within the 
first year of diagnosis and therefore could have other forms of diabetes. Incident cases 
(relative to UK Biobank baseline visit) of T2D were included using Hospital Episode 
Statistics (HES) data (from ICD10 code: E11.*). In addition, having any form of diabetes 
was defined for individuals who reported being informed of having the disease by their 
doctor (UK Biobank data field 2443). CAD was defined from HES and self-reported data 
from the UK Biobank questionnaire at baseline. Reporting of angina and/or myocardial 
infarction was used as criteria. CKD was defined using relevant primary and secondary 
ICD9 (580-629) and ICD10 codes (N00 to N99) available from HES data. Stroke was 
defined using codes 1583 (ischaemic stroke), 1081 (stroke), 1086 (subarachnoid 
haemorrhage) and 1491 (brain haemorrhage) from clinic nurses’ codes for non-cancer 
illness (UK Biobank data field 20002). 
 
Investigating the overlap of loci associated with ACR with other traits from previous 
genome-wide association studies. 
We downloaded association statistics from the NHGRI-EBI GWAS Catalog (17). We 
looked up lead SNPs for ACR and proxies (r
2 
> 0.8) against SNPs catalogued with P-
value<5x10
-8
.  
 
Colocalization analysis of ACR-associated SNPs associated with other traits 
We performed colocalization analysis to determine the likelihood of shared causal 
variants at associated loci that overlap for other traits in the GWAS catalog. We used 
summary statistics for SNPs 500Kb either-side of the lead ACR-associated variant using 
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publicly available genome-wide association study data (16, 26-32), aligning the effects to 
the ACR effect alleles. We used the coloc.abf function to estimate the probability of each 
locus sharing a causal variant. 
 
Gene-set and tissue enrichment analyses 
Gene-set analyses and tissue expression analyses were performed using MAGMA (14) as 
implemented in the online Functional Mapping and Annotation of Genome-Wide 
Association Studies (FUMA) tool (33). 
 
Haplotype estimation and testing of associated SNPs in the CUBN locus 
Estimation and testing of haplotypes were performed using UNPHASED (version 3.1.7) 
(34). Genotypes were converted to best-guess genotypes (0, 1, or 2) prior to haplotype 
estimation. Effect estimates were made relative to the reference haplotype comprising of 
the common alleles. This analysis was performed in a subset of 367,882 unrelated UK 
Biobank individuals (<3
rd
 degree relatives). 
 
Interaction analyses. We performed interaction analyses for both novel and previously 
reported (5) SNPs to test for differences in effect sizes between diabetes cases and 
controls. These analyses were performed in the unrelated subset of 367,882 UK Biobank 
individuals. Of these, we classified 17,671 as having some form of diabetes. We 
compared effect sizes in diabetes cases versus controls by fitting the multiplicative 
interaction model and testing if not equal to zero - specifically:  
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ACR = SNPACR + diabetescase/control + SNPACR×diabetescase/control [+ covariates] 
(3) 
 
Negative control experiment to test specificity of interactions. We tested whether putative 
interactions were specific to the interacting condition (e.g. diabetes), or an artefact of the 
highly skewed distribution. Using a computational optimization (genetic) algorithm (url: 
https://github.com/drarwood/gags), we repeatedly sampled individuals from the UK 
Biobank to derive groups matched to the ACR distributions of diabetes cases and controls 
but randomized to diabetes status. We repeated this random sampling 1,000 times and 
compared the results to the observed interaction (15). 
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FIGURE LEGENDS 
 
Figure 1. Significance of SNP associations for three independent signals at the CUBN 
locus. A) association of SNPs from the initial GWAS analysis, B) strength of SNP 
associations after the first round of conditional analysis, and C) strength of SNP 
associations after the second round of conditional analysis. 
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Figure 2. ACR by CUBN genotype group. ACR mean values and standard deviations by 
genotype group based on SNPs in the CUBN locus. Solid black line is the clinical 
threshold for microalbuminuria.  
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TABLES 
 
Table 1. Characteristics of participants from the UK Biobank and EXTEND 
analysed. Data presented as mean (±standard deviation) or median [25
th
 -75
th
 percentile] 
where not otherwise stated.  
 
 
  UK Biobank EXTEND 
N 437,027 5,679 
Age (years) 57.28 (± 8.02) 54.31 (± 14.83) 
Sex (%Female - %Male) 54.18 - 45.82 62.85 - 37.15 
Height (cm) 168.7 (± 9.2) 168.5 (± 9.1) 
BMI 27.38 (± 4.74) 26.52 (± 4.62) 
ACR (mg/mml) 1.08 [0.68 - 1.82] 0.73 [0.42 - 1.34] 
CAD  (%Yes - %No) 10.47 - 89.53 3.79 - 96.21 
T2D  (%Yes - %No) 3.17 - 96.83 1.04 - 98.96 
Systolic BP (mmHg) 144.2 (± 24.0) 131.1 (± 19.8) 
Diastolic BP (mmHg) 86.3 (± 13.5) 77.4 (± 10.8) 
 
ACR = albumin-creatinine ratio; CAD = coronary artery disease; T2D = type 2 diabetes; 
BP = blood pressure.  
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Table 2. GWAS summary statistics in the UK Biobank for the 20 SNPs located in loci not previously 
reported or in low linkage disequilibrium (r
2
<0.1) with lead SNPs previously reported. Comparisons 
with publicly available data from the CKDGen consortium and lookups in the EXTEND study can be found 
in Supplementary Tables 2 and 3, respectively. 
 
Nearest Gene SNP Chr 
Position 
(b37) EA/OA EA Freq Beta SE P 
MST01 rs35202981 1 155578042 G/A 0.139 0.017 0.003 1.4E-08 
EDEM3 rs78444298 1 184672098 G/A 0.980 0.045 0.007 1.4E-09 
GPD2 rs111688960 2 157599687 A/G 0.013 0.051 0.009 1.2E-08 
FAT1 rs62342738 4 187656129 C/G 0.181 0.015 0.003 5.5E-09 
C5orf56 rs11242113 5 131777234 A/G 0.188 0.016 0.003 1.6E-09 
KCNK5 rs1544935 6 39124448 G/T 0.216 0.017 0.002 2.2E-11 
VEGFA rs3734692 6 43817791 T/A 0.310 0.016 0.002 1.8E-13 
AUTS2 rs35692677 7 69902654 G/A 0.813 0.015 0.003 1.1E-08 
ZBTB1 rs11990607 8 81363534 A/G 0.835 0.015 0.003 2.5E-08 
MLLT10 rs6482189 10 21889138 G/A 0.683 0.013 0.002 1.6E-09 
CYP26A1  rs2068888 10 94839642 G/A 0.550 0.012 0.002 1.0E-09 
SBF2 rs11042685 11 10262551 C/T 0.493 0.011 0.002 2.1E-08 
NUMA1 rs7115200 11 71752160 G/T 0.440 0.012 0.002 1.4E-09 
OAF rs12790943 11 120058623 T/C 0.421 0.011 0.002 3.0E-08 
NAV3 rs10860332 12 78748014 A/G 0.414 0.011 0.002 4.4E-08 
DLEU1/BCMS rs3116613 13 51143055 G/T 0.211 0.014 0.002 3.9E-08 
WDR81 rs550628400 17 1639795 G/A 0.006 0.075 0.013 2.1E-08 
CYP2A7 rs79600176 19 41392490 T/C 0.978 0.038 0.007 3.6E-08 
CCDC97 rs56254331 19 41826020 A/C 0.831 0.017 0.003 7.9E-10 
ZBTB46 rs11697610 20 62379531 G/A 0.387 0.012 0.002 1.9E-08 
 
SNP = single nucleotide polymorphism; b37 = build 37; EA/OA = effect allele / other allele; 
Freq = Frequency; SE = standard error; P = P-value. 
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Table 3. Independent signals identified at the CUBN locus on chromosome 10. Associations in the CUBN locus with ACR in UK Biobank 
whole cohort. Univariable results when each SNP is entered individually and multivariable results when all three SNPs are entered in the same 
regression model. 
 
  SNP 
Position 
(b37) 
Effect/Other 
Allele 
Frequency 
Effect Allele Model Beta SE P 
 
rs141640975 10:16992011 A/G 0.003 
Univariable 0.463 0.022 4E-99 
 Multivariable 0.470 0.022 3E-102 
CUBN 
rs45551835 10:16932384 A/G 0.014 
Univariable 0.188 0.009 2E-90 
  Multivariable 0.156 0.010 1E-56 
 
rs45619139 10:16940846 G/C 0.101 
Univariable 0.059 0.004 1E-57 
  Multivariable 0.040 0.004 7E-25 
 
SNP = single nucleotide polymorphism; b37 = build 37; SE = standard error; P = P-value
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Table 4. Haplotype associations with ACR based on the 3 SNPs in the CUBN locus. 
Effect sizes are given in standard deviations of inverse-normalized ACR and are relative to 
the baseline haplotype group formed by the three common alleles of the three SNPs. The 2 
test statistics and P-values for each haplotype correspond to the significance of the 
association when compared against all other haplotypes pooled. Alleles are ordered across 
haplotypes based on genomic position and represent 1) the low-frequency variant 
rs45551835, 2) the common variant rs45619139, and 3) the rare variant rs141640975. 
 
 
Haplotype Frequency Additive Effect 95% CI 
2
 P 
G-C-G (000) 0.895 REF REF 352.7 1E-78 
G-G-G (010) 0.086 0.039 0.031, 0.047 72.6 2E-17 
A-G-G (110) 0.013 0.201 0.181, 0.221 370.1 2E-82 
G-C-A (001) 0.003 0.482 0.437, 0.527 421.9 2E-94 
A-C-G (100) 0.001 0.138 0.065, 0.211 15.2 1E-04 
 
95% CI = ninety-five percent confidence interval; 2= chi-squared test statistic; P = P-value  
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Table 5. Associations of the three statistically independent SNPs at the CUBN locus within individuals with diabetes and without 
diabetes. The interaction term with diabetes is presented. Empirical P refers to the control experiment that involved the repeated sampling of 
two groups (x1,000) matched on the distributions of ACR observed in individuals with- and without diabetes prior to interaction analysis of the 
dummy group variable. 
 
 
    Individuals with diabetes Individuals  without diabetes Interaction Term 
SNP Effect Allele Beta SE P Beta SE P Beta SE P 
Empirical 
P 
rs45551835 A 0.358 0.044 3.8E-16 0.179 0.010 1.4E-78 0.213 0.043 6E-07 0.001 
rs45619139 G 0.115 0.017 4.7E-11 0.055 0.004 3.7E-49 0.075 0.017 1E-05 0.002 
rs141640975 A 0.781 0.107 2.6E-13 0.449 0.022 1.3E-89 0.426 0.104 4E-05 0.020 
 
SNP = single nucleotide polymorphism; SE = standard error; P = P-value
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ABBREVIATIONS 
 
ACR  Albumin-creatinine ratio 
CAD  Coronary artery disease 
CI  Confidence interval 
CKD  Chronic kidney disease 
EXTEND Exeter 10,000  
GRS  Genetic risk score 
GWAS Genome-wide association study 
HES  Hospital Episode Statistic 
HRC  Haplotype Reference Consortium 
ICD  International Classification of Diseases 
LD  Linkage disequilibrium 
MAF  Minor allele frequency 
OR  Odds Ratio 
SD  Standard Deviation 
SNP  Single nucleotide polymorphism 
T2D  Type 2 diabetes 
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